Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid with Neoadjuvant Chemotherapy in TNBC
NCT06876636Phase 2Active, not recruiting
- Sponsor
- Xijing Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zoledronic acid in triple-negative breast cancer (TNBC), sponsored by Xijing Hospital. Primary endpoint: Pathological Complete Response rate at 6 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
zoledronic acid
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06876636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06876636.